Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a global company that produces medical devices for use in various procedures and treatments. They have a diverse product portfolio, strong profitability, and potential for growth through new products and recent acquisitions. While there are risks such as potential macroeconomic challenges and competition, their sales growth and profitability metrics support a positive outlook. The company's recent announcement of reduced growth expectations for their Watchman LAAC franchise may have impacted investor confidence, but the company's long-range plan shows potential for continued growth.

Bears say

Boston Scientific is facing challenges in its key product markets, such as slower growth in Watchman procedures and losing market share in Farapulse PFA and Urology. These challenges have led management to revise downward its full-year revenue guidance and lower its Q2 outlook, causing near-term negative sentiment. Additionally, while Boston Scientific maintains bottom-line expectations, there are concerns about their ability to offset the lower revenue expectations and the potential for a Long-Range Plan reset. However, Boston Scientific is undervalued and has a strong product pipeline and impressive profitability metrics, which could lead to margin expansion and double-digit adjusted EPS growth.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jul 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.